

**REGULATORY AFFAIRS IN PHARMACEUTICAL PRODUCT
DEVELOPMENT: A COMPREHENSIVE REVIEW**

**Sai Phanindra Yarra^{1*}, Pavan Chennupati², Boya Shirisha¹, Potturi Pravallika¹,
Syed Pedda Shan¹**

¹Department of Regulatory Affairs, Chennupati Indo-American School of Pharmacy,
Narasaraopet, 522601, Andhra Pradesh, India.

²Department of Pharmaceutical Chemistry, Chennupati Indo-American School of Pharmacy,
Narasaraopet, 522601, Andhra Pradesh, India.

Article Received on 07 July 2026,
Article Revised on 28 July 2026,
Article Published on 01 Aug 2026,
<https://doi.org/10.5281/zenodo.21772992>

Corresponding Author*Sai Phanindra Yarra**

Department of Regulatory affairs,
Chennupati Indo-American School
of Pharmacy, Narasaraopet, 522601,
Andhra Pradesh, India.



How to cite this Article: Sai Phanindra Yarra^{1*}, Pavan Chennupati², Boya Shirisha¹, Potturi Pravallika¹, Syed Pedda Shan¹. (2026). Regulatory Affairs In Pharmaceutical Product Development: A Comprehensive Review. World Journal of Pharmaceutical Research, 15(15), 1987–2001.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Pharmaceutical product development is a complex and highly regulated process that ensures medicines are safe, effective, and of high quality before they reach patients. Regulatory affairs play a central role in coordinating scientific, technical, and legal requirements throughout the product life cycle, from early research and development to post-marketing surveillance. Regulatory professionals work closely with research, manufacturing, quality assurance, and clinical teams to ensure compliance with national and international regulations. They are responsible for preparing regulatory submissions, maintaining communication with health authorities, and ensuring that pharmaceutical products meet applicable standards for approval and marketing. In recent years, globalization, harmonization of regulatory guidelines, and advances in digital technologies have significantly influenced

regulatory practices. This review highlights the importance of regulatory affairs in pharmaceutical product development, discusses the major regulatory authorities and essential guidelines, outlines key regulatory responsibilities during product development, and summarizes current challenges and future perspectives in the field.

KEYWORDS: Pharmaceutical Regulatory Affairs, Product Development, Drug Approval,

Regulatory Compliance, CDSCO, US FDA, EMA, ICH, GMP.

1. INTRODUCTION

1.1 Evolution of Pharmaceutical Regulation

The pharmaceutical industry plays a crucial role in improving global health through the discovery, development, manufacture, and distribution of medicines for the prevention and treatment of diseases. Unlike other consumer products, pharmaceutical products directly influence human health and therefore require rigorous evaluation before they are made available to the public. Medicines that are ineffective, contaminated, or poorly manufactured can result in serious health consequences, making regulatory oversight an essential component of the pharmaceutical sector.^[1-3]

In the past, limited regulatory control allowed several unsafe medicines to enter the market, leading to adverse public health outcomes. Such incidents emphasized the need for comprehensive legislation governing the development, manufacture, and marketing of pharmaceutical products.^[4,5] Consequently, governments established regulatory authorities and implemented laws to ensure that medicines meet predefined standards of quality, safety, and efficacy. Over time, pharmaceutical regulation has evolved into a scientific and legal framework that oversees every stage of a product's life cycle, from early research and development to post-marketing surveillance. Today, regulatory systems not only protect public health but also promote innovation, ethical research, and international confidence in pharmaceutical product.^[2,3,5]

1.2 Pharmaceutical Regulatory Affairs

Regulatory affairs is a specialized discipline within the pharmaceutical industry that ensures compliance with national and international regulatory requirements throughout the product life cycle. It serves as the link between pharmaceutical companies and regulatory authorities by coordinating scientific, technical, and legal activities necessary for product approval and lifecycle management.^[6,7]

The primary objective of regulatory affairs is to ensure that pharmaceutical products are developed, manufactured, and marketed in accordance with applicable regulations while maintaining high standards of quality, safety, and efficacy. Regulatory professionals participate in planning development strategies, interpreting regulatory guidelines, preparing regulatory submissions, responding to agency queries, and maintaining product approvals

after commercialization. They also collaborate with multidisciplinary teams including research and development, quality assurance, manufacturing, clinical research, pharmacovigilance, and marketing to ensure that regulatory requirements are incorporated throughout product development.^[8,9]

The importance of regulatory affairs has increased considerably with the globalization of pharmaceutical markets, rapid scientific advancements, and continuous revision of regulatory requirements. Modern regulatory professionals are expected to possess scientific knowledge, regulatory expertise, communication skills, and strategic planning abilities to facilitate efficient product development and timely market authorization. Their contribution helps pharmaceutical companies achieve regulatory compliance while reducing development delays and improving patient access to safe and effective medicines.^[10,11]

1.3 Regulatory Affairs in Pharmaceutical Product Development

Pharmaceutical product development is a systematic and multidisciplinary process involving drug discovery, preclinical evaluation, clinical research, manufacturing, regulatory review, commercialization, and post-marketing surveillance. Each stage generates scientific evidence that demonstrates the quality, safety, and efficacy of the product before it can receive marketing authorization. Regulatory affairs plays an essential role throughout this process by ensuring that development activities comply with applicable regulatory standards and scientific guidelines.^[12,13]

The involvement of regulatory affairs begins during the early stages of product development by providing regulatory guidance on development strategies, documentation requirements, and applicable regulatory pathways. During preclinical and clinical development, regulatory professionals coordinate the preparation of study-related submissions, ensure compliance with ethical and scientific standards, and facilitate communication with regulatory authorities. Their expertise supports efficient study planning, minimizes regulatory deficiencies, and improves the quality of data submitted for regulatory evaluation.^[14,15]

As product development progresses, regulatory affairs coordinates the preparation of comprehensive marketing authorization applications containing information on pharmaceutical quality, manufacturing, non-clinical studies, clinical trial results, labeling, and risk management. Well-prepared regulatory submissions contribute to efficient review by regulatory agencies and increase the likelihood of timely product approval.^[16,17]

The responsibilities of regulatory affairs continue after marketing authorization through lifecycle management activities such as product variations, labeling updates, regulatory renewals, pharmacovigilance, and compliance with regulatory inspections. Continuous monitoring of regulatory changes and maintenance of product compliance are essential to ensure uninterrupted product availability and patient safety. Therefore, regulatory affairs is not limited to obtaining product approval but represents a continuous process that supports pharmaceutical innovation while maintaining regulatory compliance throughout the product lifecycle.^[18]

1.4 Global Regulatory Environment and Scope of the Review

The globalization of pharmaceutical development has increased the need for harmonized regulatory requirements across different countries. International organizations such as the International Council for Harmonisation (ICH) have developed globally accepted guidelines that promote consistency in pharmaceutical quality, safety, efficacy, and regulatory documentation. Harmonization reduces duplication of studies, facilitates international product registration, and supports the availability of safe and effective medicines worldwide.^[22,24]

Major regulatory authorities, including the Central Drugs Standard Control Organization (CDSCO), the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and other national agencies, continue to strengthen regulatory systems by adopting science-based approaches for the evaluation of pharmaceutical products. Simultaneously, emerging technologies such as biologics, gene therapies, digital health, and artificial intelligence have introduced new regulatory challenges, requiring continuous adaptation of regulatory frameworks.^[22–24]

This review provides an overview of the role of regulatory affairs in pharmaceutical product development, highlighting its contribution throughout the product lifecycle, major regulatory requirements, regulatory authorities and guidelines, documentation practices, current challenges, and future perspectives. Understanding these aspects is essential for pharmaceutical scientists, regulatory professionals, researchers, and healthcare practitioners involved in the successful development and commercialization of pharmaceutical products.^[19,20]

2. Pharmaceutical Product Development Process

Pharmaceutical product development is a systematic, multidisciplinary, and highly regulated process through which a potential drug candidate is transformed into a safe, effective, and high-quality medicinal product for clinical use. The process involves interconnected scientific, technical, and regulatory activities that ensure medicines meet established standards of quality, safety, and efficacy. Developing a new pharmaceutical product is a lengthy and resource-intensive process requiring several years of research, laboratory investigations, clinical evaluation, regulatory review, and quality assurance before marketing approval. Since only a small proportion of drug candidates successfully complete all development stages, careful planning and adherence to regulatory and scientific principles are essential throughout product development.^[19–21,26,27]

The development process begins with drug discovery, where disease targets are identified and numerous compounds are screened to discover molecules with potential therapeutic activity. Modern approaches include computational drug design, high-throughput screening, molecular modeling, and biotechnology. Lead compounds are optimized to improve efficacy, selectivity, stability, and safety before advancing to further development.^[20,21,26,27]

Following successful drug discovery, the selected candidate enters preclinical development. Laboratory and animal studies evaluate pharmacological activity, pharmacokinetic characteristics, and toxicological profiles. Formulation development is also performed to ensure product stability and quality before human studies.^[21,25]

If preclinical studies are satisfactory, the product proceeds to clinical development involving Phase I, II, III, and IV clinical trials to evaluate safety, dosage, efficacy, and long-term safety. Clinical trials follow internationally accepted ethical and scientific standards to ensure reliable evidence for regulatory approval.^[19,22,23]

Pharmaceutical development and manufacturing ensure consistent product quality through process optimization, validation, stability testing, equipment qualification, and quality assurance. Manufacturing processes must consistently produce products meeting predefined quality specifications.^[25]

Following successful pharmaceutical development and clinical evaluation, a comprehensive regulatory dossier is submitted for marketing authorization. Regulatory agencies assess

quality, manufacturing, preclinical, clinical, labeling, and risk management data before determining whether the product's benefits outweigh its potential risks.^[22,23]

Following approval, commercial manufacturing and product distribution begin. Manufacturing batches undergo rigorous quality control testing, while appropriate packaging, storage, and transportation maintain product quality throughout the supply chain.^[25]

Pharmaceutical product development continues after market authorization through post-marketing surveillance. Adverse drug reactions, medication errors, and product quality complaints are continuously monitored to improve patient safety and support evidence-based regulatory decisions.^[23,24]

Continuous product improvement includes formulation modifications, manufacturing improvements, packaging changes, additional strengths, and new therapeutic indications. These changes undergo scientific and regulatory evaluation before implementation to ensure continued quality, safety, and efficacy.^[24,25]

Modern pharmaceutical product development has become increasingly technology-driven through biotechnology, artificial intelligence, computational modeling, personalized medicine, and digital health technologies. These innovations have improved drug discovery, clinical development, manufacturing efficiency, and global product registration while increasing collaboration among multidisciplinary teams.^[20,23,24,27]

3. Role of Regulatory Affairs in Pharmaceutical Product Development

Regulatory affairs is a key function in pharmaceutical product development, ensuring that medicinal products comply with applicable regulatory requirements throughout their lifecycle. It serves as the interface between pharmaceutical companies and regulatory authorities by coordinating scientific, technical, and legal activities required for product approval and continued market compliance. The primary objective of regulatory affairs is to facilitate the development and commercialization of safe, effective, and high-quality pharmaceutical products while ensuring adherence to national and international regulations.^[28,29]

The involvement of regulatory affairs begins during the early stages of product development. Regulatory professionals provide strategic guidance on applicable regulatory pathways, relevant guidelines, and documentation requirements before the initiation of preclinical and

clinical studies. Early regulatory planning helps identify potential challenges, optimize development strategies, and reduce delays during product registration. Their input ensures that the data generated throughout development meet regulatory expectations and support successful marketing authorization.^[28,33,34]

During preclinical and clinical development, regulatory affairs coordinates the preparation and submission of regulatory applications, study protocols, investigator brochures, informed consent documents, and safety reports. Regulatory professionals also maintain communication with health authorities, respond to regulatory queries, and ensure that development activities comply with applicable scientific, ethical, and legal requirements. Their involvement promotes data integrity, regulatory compliance, and efficient progression of clinical development.^[29,30]

Regulatory affairs also plays an essential role in the preparation of marketing authorization applications. It coordinates the compilation of pharmaceutical quality information, manufacturing data, non-clinical studies, clinical trial results, product labeling, and risk management information into a structured regulatory dossier. The accuracy, completeness, and consistency of these submissions are critical for efficient regulatory review and timely product approval.^[29,30]

After marketing authorization, the responsibilities of regulatory affairs continue through product lifecycle management. This includes managing product variations, license renewals, labeling updates, safety reporting, and regulatory commitments. Regulatory professionals monitor changes in national and international regulations and ensure that approved products remain compliant with evolving regulatory requirements.^[31,32]

The globalization of the pharmaceutical industry has significantly expanded the scope of regulatory affairs. Pharmaceutical companies frequently seek product approval in multiple countries, each with distinct regulatory frameworks and submission requirements. Regulatory professionals develop global regulatory strategies, adapt documentation to country-specific requirements, and coordinate simultaneous submissions across different regulatory agencies. International harmonization initiatives have simplified many aspects of global registration; however, differences in national regulations continue to require specialized regulatory expertise.^[28,29,38]

Advances in pharmaceutical science and digital technologies have further transformed regulatory affairs. Electronic submissions, regulatory information management systems, artificial intelligence, and digital document management have improved the efficiency of regulatory operations and communication with regulatory agencies. In addition, the emergence of biologics, biosimilars, gene therapies, and personalized medicines has increased the need for specialized regulatory knowledge and adaptive regulatory strategies.^[31,39]

Overall, regulatory affairs is a strategic component of pharmaceutical product development that supports scientific innovation while ensuring regulatory compliance. Its responsibilities extend from early product development through post-marketing activities, contributing to efficient product approval, continuous regulatory compliance, and patient safety.^[28–32]

4. Regulatory Authorities and Guidelines

Pharmaceutical products are regulated by national and international authorities to ensure that medicines marketed to the public are safe, effective, and of consistent quality.^[29,38]

In India, the Central Drugs Standard Control Organization (CDSCO) functions as the national regulatory authority under the Ministry of Health and Family Welfare. Headed by the Drugs Controller General of India (DCGI), CDSCO is responsible for approving new drugs, granting permission for clinical trials, regulating the import of pharmaceuticals, coordinating drug standards, and ensuring compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.^[29,38]

The United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Therapeutic Goods Administration (TGA) regulate pharmaceutical products within their respective jurisdictions.^[29,38]

The International Council for Harmonisation (ICH) develops internationally accepted guidelines covering Quality, Safety, Efficacy, and Multidisciplinary topics, thereby promoting harmonized pharmaceutical development and regulatory submissions.^[28,30]

The World Health Organization (WHO) contributes by publishing technical guidance on good manufacturing practices, quality assurance, pharmacovigilance, and essential medicines while strengthening regulatory systems worldwide.^[31]

Compliance with Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Pharmacovigilance Practice (GVP) enhances data reliability, product quality, and patient safety while facilitating regulatory acceptance across different regions.^[30,31]

Overall, regulatory authorities and harmonized guidelines provide the scientific and legal framework that governs pharmaceutical product development and promotes global regulatory compliance.^[28–31]

5. Regulatory Documentation and Submission Process

Regulatory documentation provides scientific evidence demonstrating the quality, safety, and efficacy of pharmaceutical products. Well-prepared documentation facilitates regulatory review, minimizes deficiencies, and supports timely product approval.^[29,30]

The Common Technical Document (CTD) developed through the International Council for Harmonisation (ICH) standardizes regulatory submissions into five modules, allowing pharmaceutical companies to prepare a common dossier for multiple regulatory authorities.^[28,30]

The Electronic Common Technical Document (eCTD) enables electronic submission, review, document tracking, and lifecycle management, thereby improving regulatory efficiency.^[29,31]

Regulatory affairs professionals coordinate contributions from multidisciplinary teams, prepare complete regulatory dossiers, and ensure that submissions comply with applicable scientific and regulatory requirements.^[28,29]

Following submission, regulatory agencies evaluate the dossier, request clarification where necessary, and determine whether the available evidence supports marketing authorization.^[29,38]

After approval, regulatory documentation continues through product variations, labeling updates, manufacturing changes, periodic safety reports, and license renewals, ensuring continued regulatory compliance throughout the product lifecycle.^[31,32]

6. Challenges and Future Perspectives

The field of pharmaceutical regulatory affairs is continuously evolving due to scientific advancements, globalization, and increasing regulatory expectations. Regulatory professionals must adapt to frequent changes in legislation, emerging technologies, and updated international guidelines while ensuring continuous regulatory compliance throughout the product lifecycle.^[44,45]

One of the major challenges is the variation in regulatory requirements among different countries. Although harmonization initiatives have reduced many differences, pharmaceutical companies seeking global product registration must still comply with country-specific regulations, documentation requirements, and approval procedures. Preparing multiple submissions while maintaining consistency requires considerable expertise and coordination.^[40,45]

Another important challenge is the rapid advancement of pharmaceutical technologies. The development of biologics, biosimilars, cell and gene therapies, personalized medicines, nanomedicines, and digital health products has introduced new scientific and regulatory complexities. Consequently, regulatory agencies continue to update their scientific and regulatory frameworks to accommodate these innovations.^[40,44,45]

Maintaining data integrity and regulatory compliance throughout the product lifecycle is also a significant responsibility. Pharmaceutical companies must ensure accurate documentation, effective quality management systems, robust pharmacovigilance, and timely reporting of product changes and safety information. Failure to comply with regulatory requirements may result in inspection findings, product recalls, regulatory delays, or withdrawal of marketing authorization.^[41–43]

Digital transformation is reshaping regulatory affairs by improving the efficiency of regulatory submissions and document management. The adoption of electronic Common Technical Document (eCTD) submissions, regulatory information management systems, cloud-based document repositories, and artificial intelligence has enhanced data organization,

submission tracking, and regulatory communication, thereby improving regulatory efficiency and decision-making.^[40,41]

Looking ahead, regulatory affairs is expected to become increasingly strategic and science-driven. Greater international harmonization, wider use of real-world evidence, digital technologies, and collaborative regulatory approaches are likely to improve the efficiency of pharmaceutical regulation. Strengthened cooperation among regulatory authorities, academic institutions, healthcare professionals, and the pharmaceutical industry will further support pharmaceutical innovation while maintaining high standards of quality, safety, and efficacy. Consequently, regulatory affairs will continue to play a pivotal role in ensuring timely patient access to safe, effective, and high-quality medicines.^[40–45]

CONCLUSION

Regulatory affairs is an integral component of pharmaceutical product development, ensuring that medicinal products comply with regulatory requirements from early research to post-marketing surveillance. By coordinating scientific, technical, and legal activities, regulatory professionals facilitate the development, approval, and lifecycle management of pharmaceutical products while maintaining high standards of quality, safety, and efficacy. Their collaboration with research, clinical, manufacturing, and quality teams supports efficient regulatory submissions, timely product approvals, and continued regulatory compliance.

The increasing globalization of the pharmaceutical industry and the emergence of advanced therapeutic technologies have expanded the scope and importance of regulatory affairs. Harmonized international guidelines, digital regulatory systems, and evolving regulatory frameworks continue to improve the efficiency of product evaluation while promoting innovation and patient safety. However, differences in regulatory requirements, rapidly changing guidelines, and technological advancements remain significant challenges for the pharmaceutical industry.

Overall, effective regulatory affairs contributes to the successful development and commercialization of pharmaceutical products by ensuring compliance with national and international regulations. As pharmaceutical science continues to evolve, regulatory affairs will remain a strategic discipline that supports innovation, facilitates global market access,

and ultimately ensures that safe, effective, and high-quality medicines reach patients worldwide.

ACKNOWLEDGEMENTS

The authors express their sincere gratitude to their institution and colleagues for their encouragement and support during the preparation of this review article.

FUNDING

The authors declare that no external funding was received for this work.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this review article.

REFERENCES

1. Kaitin KI. Deconstructing the drug development process: the new face of innovation. *Clin Pharmacol Ther.*, 2010; 87(3): 356-361.
2. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov*, 2012; 11(3): 191-200.
3. Van Norman GA. Drugs, devices, and the FDA: part 1. An overview of approval processes for drugs. *JACC Basic Transl Sci.*, 2016; 1(3): 170-179.
4. Junod SW. FDA and clinical drug trials: a short history. *Food Drug Law J.*, 2008; 63(2): 151-194.
5. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton University Press, 2010.
6. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investig*, 2012; 2(3): 99-105. doi:10.4103/2230-973X.104392.
7. Gupta YK, Kumar BD. Clinical trials and evolving regulatory science in India. *Indian J Pharmacol*, 2014; 46(6): 575-578. doi:10.4103/0253-7613.144887.
8. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investig*, 2012; 2(3): 99-105. doi:10.4103/2230-973X.104392.
9. Chakraborty K, Yadav K. Drug approval process in US, Europe and India and its regulatory requirements: A review. *Int J Drug Regul Aff*, 2018; 6(3): 31-39.

10. Gupta SK, Nayak RP. Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities. *J Pharmacol Pharmacother*, 2014; 5(2): 88-92.
11. Rathore AS. Guidelines on similar biologics: Regulatory requirements for marketing authorization in India. *PDA J Pharm Sci Technol*, 2012; 66(5): 393.
12. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investig*, 2012; 2(3): 99-105.
13. Chakraborty K, Yadav K. Drug approval process in US, Europe and India and its regulatory requirements: A review. *Int J Drug Regul Aff.*, 2018; 6(3): 31-39.
14. Gupta YK, Kumar BD. Clinical trials and evolving regulatory science in India. *Indian J Pharmacol*, 2014; 46(6): 575-578.
15. Patel VJ, Patel DM. A comprehensive review on registration requirements for drug approval in India, South Africa and US. *Int J Drug Regul Aff.*, 2021; 9(1): 1-10.
16. Van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. *JACC Basic Transl Sci.*, 2016; 1(3): 170-179.
17. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investig*, 2012; 2(3): 99-105.
18. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision-making: Challenges and possible solutions for Europe. *Clin Pharmacol Ther.*, 2019; 106(1 36-39).
19. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J Health Econ*, 2016; 47: 20-33. doi:10.1016/j.jhealeco.2016.01.012.
20. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov*, 2012; 11(3): 191-200. doi:10.1038/nrd3681.
21. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol*, 2011; 162(6): 1239-1249. doi:10.1111/j.1476-5381.2010.01127.x.
22. Van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. *JACC Basic Transl Sci.*, 2016; 1(3): 170-179. doi:10.1016/j.jacbts.2016.03.002.

23. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—What is it and what can it tell us? *N Engl J Med.*, 2016; 375(23): 2293-2297. doi:10.1056/NEJMs1609216.
24. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: Challenges and possible solutions for Europe. *Clin Pharmacol Ther.*, 2019; 106(1): 36-39. doi:10.1002/cpt.1426.
25. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. *AAPS J.*, 2014; 16(4): 771-783. doi:10.1208/s12248-014-9598-3.
26. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov*, 2004; 3(8): 711-715. doi:10.1038/nrd1470.
27. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. *Nat Rev Drug Discov*, 2014; 13(6): 419-431. doi:10.1038/nrd4309.
28. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investig*, 2012; 2(3): 99-105.
29. Van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. *JACC Basic Transl Sci.*, 2016; 1(3): 170-179.
30. Yu LX, Amidon G, Khan MA, Hoag SW, Polli JE, Raju GK, et al. Understanding pharmaceutical quality by design. *AAPS J.*, 2014; 16(4): 771-783.
31. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: Challenges and possible solutions for Europe. *Clin Pharmacol Ther.*, 2019; 106(1): 36-39.
32. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—What is it and what can it tell us? *N Engl J Med.*, 2016; 375(23): 2293-2297.
33. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol*, 2011; 162(6): 1239-1249.
34. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J Health Econ.*, 2016; 47: 20-33.
35. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov*, 2012; 11(3): 191-200.
36. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov*, 2004; 3(8): 711-715.

37. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. *Nat Rev Drug Discov*, 2014; 13(6): 419-431.
38. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. *Annu Rev Med.*, 2008; 59: 1-12.
39. Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real-world evidence: Neither magic nor myth. *Clin Pharmacol Ther.*, 2021; 109(5): 1212-1218.
40. Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real-world evidence: Neither magic nor myth. *Clin Pharmacol Ther.*, 2021; 109(5): 1212-1218.
41. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: Challenges and possible solutions for Europe. *Clin Pharmacol Ther.*, 2019; 106(1): 36-39.
42. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—What is it and what can it tell us? *N Engl J Med.*, 2016; 375(23): 2293-2297.
43. Yu LX, Amidon G, Khan MA, Hoag SW, Polli JE, Raju GK, et al. Understanding pharmaceutical quality by design. *AAPS J.*, 2014; 16(4): 771-783.
44. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. *Annu Rev Med.*, 2008; 59: 1-12.
45. Van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. *JACC Basic Transl Sci.*, 2016; 1(3): 170-179.